Navigation Links
Proof of Concept Study Shows Protection with Influenza Vaccine

COLUMBIA, Md., April 24, 2013 /PRNewswire/ -- Royal DSM, a global life sciences and materials sciences company, announced today the results of a proof of concept study that demonstrated efficacy of an influenza vaccine developed and produced by a commercial microalgal platform system. The study results were published today in the peer-reviewed journal, PLOS ONE. In this study, the researchers used DSM's proprietary Schizochytrium platform to produce a subunit influenza vaccine capable of preventing disease in mice. Schizochytrium is currently used to produce nutritional lipids for supplements and fortification of foods. The vaccine was made using this basic commercial process, which is faster and less expensive than other comparable pharmaceutical processes.

"Higher-yield, lower-cost, and faster influenza vaccine production processes are critical to meet the global supply and surge production capabilities needed to counter global epidemic and pandemic threats," says Casey Lippmeier , a senior scientist at DSM who led the study.

This new Schizochytrium cell-based process has the potential to reduce vaccine scale-up and manufacture to less than half the time of the current egg-based system.  Traditionally, common influenza vaccines have been created from inactivated or attenuated preparations of live virus cultured in chicken eggs.  The current egg-based system is a labor intensive process requiring one or two eggs per vaccine dose and more than six months to scale-up for commercial manufacturing. 

"This production system facilitates development of new flu vaccines with earlier availability ahead of flu season, multivalent formulations for protection against a greater number of flu strains, and potentially better matching of the flu vaccine to the strains circulating in a given year," said Lippmeier.

Proof of Concept Study
The published study, Vaccination against Influenza with Recombinant Hemagglutinin Expressed by Schizochytrium sp. Confers Protective Immunity, can be found online at  In this study, recombinant hemagglutinin proteins of influenza virus were expressed in the microalga Schizochytrium sp., an established, fermentable organism which is routinely grown in large commercial scale (>150,000 L). Schizochytrium cells were capable of secreting full-length, membrane-bound, influenza proteins in a readily usable form for vaccine formulation. One recombinant hemagglutinin (rHA) protein derived from A/Puerto Rico/8/34 (H1N1) influenza virus was evaluated as a vaccine in a mouse challenge model.  Mice were vaccinated with a single dose of 1.7, 5 or 15 micrograms of rHA vaccine, with or without adjuvant, and then challenged with lethal levels of homologous H1N1 virus.  80-100% of the vaccinated mice survived the challenge.  Complete protection (100%) was achieved in all dose groups, with and without adjuvant, after a second vaccination.  These data demonstrate the potential of Schizochytrium sp. as a platform for the production of ready-to-use recombinant antigens for vaccination against influenza.

Schizochytrium sp. is a robustly fermentable eukaryote, best known for its ability to accumulate large amounts of cellular triglyceride containing nutritionally important polyunsaturated fatty acids (PUFA); most notably, docosahexaenoic acid (DHA). The majority of Schizochytrium-derived triglyceride oil is used to fortify foods with DHA. Schizochytrium biomass has also found use in animal applications, most commonly as a blend in poultry or aquaculture feeds to increase levels of DHA in eggs or farmed seafood, respectively. Ten tons of triglyceride oil have been produced per annum using Schizochytrium grown in fully defined, protein-free, liquid media exceeding 150,000 liter scale.  The organism is highly efficient at consuming nutrients in the presence of low dissolved oxygen levels, with a reported peak rate of 9 doublings per day. This productivity translates into lower energy, materials, and labor costs.  The oil derived from Schizochytrium are GRAS-approved with a history of beneficial use in both human and consumption.

DSM – Bright Science. Brighter Living .™
Royal DSM is a global science-based company active in health, nutrition and materials.  By connecting its unique competences in Life Sciences and Materials Sciences, DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders.  DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.  DSM's 22,000 employees deliver annual net sales of around €9 billion.  The company is listed on NYSE Euronext. More information can be found at

For more information:

Anthony Martin
tel. + 1 443-542-2599
Mobile - +1 410-818-6999

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading. Although DSM has used diligent care to ensure that the information provided herein is accurate and up to date, this publication does not constitute or provide scientific or medical advice and is distributed without warranty of any kind, either expressly or implied.

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
2. Unigenes Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
3. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
4. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
5. Proof of Concept Study Initial Findings
6. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
7. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
8. First Product in Tris Pharmas Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris
9. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
10. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At
11. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):